sales@targetmol.com (US) / info@targetmol.com    Tel: (781) 999-4286 / (781) 999-5354
Home > c-Met
c-Met
Cat.No. Product Name Information Area
T4260 Capmatinib 2HCl

INCB-28060(free base) is a novel, ATP-competitive inhibitor of c-MET kinase with a...

cancer
T3455 Merestinib LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Me... Cancer
T6907 NPS-1034 NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively. Others
T6517 Golvatinib Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growt... Cancer
T6378 AMG-458 AMG 458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Me... Cancer
T6260 AMG-208 AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1. Cancer
T6154 SU11274 SU11274(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on P... Cancer
T6128 PHA-665752 PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM)... Cancer
T6121 Tepotinib Tepotinib is an inhibitor of MET tyrosine kinase with potential antineoplastic activi... Cancer
T6117 Tivantinib Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential... Cancer
T6095 JNJ-38877605 JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective f... Cancer
T6094 MK-2461 MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a ... Cancer
T3113 Foretinib Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, with IC50 of 0.4 nM and ... Cancer
T2699 BMS-777607 BMS-777607 is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 ... Endocrine system
T2680 NVP-BVU972 NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM. Cancer
T2676 PF-04217903 MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule ty... Cancer
T2456 Tivozanib Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor r... Cancer
T2419 BMS794833 BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-8173... Cancer
T2349 BMS-754807 Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-... Cancer
T2293 SGX-523 SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p... Cancer
T2282 RPI-1 RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.? Cancer
T2054 Altiratinib Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumo... Cancer
T1963 Capmatinib Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)wit... Other
T1661 Crizotinibhot Crizotinib is a Kinase Inhibitor. The mechanism of action of crizotinib is as a Cytoc... Cancer
T6351 Glesatinib MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitar... Cancer
1